JP2022514650A5 - - Google Patents

Info

Publication number
JP2022514650A5
JP2022514650A5 JP2021535854A JP2021535854A JP2022514650A5 JP 2022514650 A5 JP2022514650 A5 JP 2022514650A5 JP 2021535854 A JP2021535854 A JP 2021535854A JP 2021535854 A JP2021535854 A JP 2021535854A JP 2022514650 A5 JP2022514650 A5 JP 2022514650A5
Authority
JP
Japan
Prior art keywords
independently selected
alkyl
alkylene
cycloalkyl
heterocycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021535854A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022514650A (ja
JP7414827B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/067403 external-priority patent/WO2020132197A1/en
Publication of JP2022514650A publication Critical patent/JP2022514650A/ja
Publication of JP2022514650A5 publication Critical patent/JP2022514650A5/ja
Priority to JP2023222944A priority Critical patent/JP7723068B2/ja
Application granted granted Critical
Publication of JP7414827B2 publication Critical patent/JP7414827B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021535854A 2018-12-20 2019-12-19 アクチビン受容体様キナーゼ-2の阻害剤としてのイミダゾピリダジン及びイミダゾピリジン化合物 Active JP7414827B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023222944A JP7723068B2 (ja) 2018-12-20 2023-12-28 アクチビン受容体様キナーゼ-2の阻害剤としてのイミダゾピリダジン及びイミダゾピリジン化合物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862782994P 2018-12-20 2018-12-20
US62/782,994 2018-12-20
US201962935891P 2019-11-15 2019-11-15
US62/935,891 2019-11-15
PCT/US2019/067403 WO2020132197A1 (en) 2018-12-20 2019-12-19 Imidazopyridazine and imidazopyridine compounds as inhibitors of activin receptor-like kinase-2

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023222944A Division JP7723068B2 (ja) 2018-12-20 2023-12-28 アクチビン受容体様キナーゼ-2の阻害剤としてのイミダゾピリダジン及びイミダゾピリジン化合物

Publications (3)

Publication Number Publication Date
JP2022514650A JP2022514650A (ja) 2022-02-14
JP2022514650A5 true JP2022514650A5 (cg-RX-API-DMAC7.html) 2022-12-08
JP7414827B2 JP7414827B2 (ja) 2024-01-16

Family

ID=69467674

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021535854A Active JP7414827B2 (ja) 2018-12-20 2019-12-19 アクチビン受容体様キナーゼ-2の阻害剤としてのイミダゾピリダジン及びイミダゾピリジン化合物
JP2023222944A Active JP7723068B2 (ja) 2018-12-20 2023-12-28 アクチビン受容体様キナーゼ-2の阻害剤としてのイミダゾピリダジン及びイミダゾピリジン化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023222944A Active JP7723068B2 (ja) 2018-12-20 2023-12-28 アクチビン受容体様キナーゼ-2の阻害剤としてのイミダゾピリダジン及びイミダゾピリジン化合物

Country Status (20)

Country Link
US (3) US11459329B2 (cg-RX-API-DMAC7.html)
EP (1) EP3898627A1 (cg-RX-API-DMAC7.html)
JP (2) JP7414827B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210116488A (cg-RX-API-DMAC7.html)
CN (2) CN114787160B (cg-RX-API-DMAC7.html)
AU (1) AU2019401649B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021011948A2 (cg-RX-API-DMAC7.html)
CA (1) CA3124088A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021001656A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021008117A2 (cg-RX-API-DMAC7.html)
CR (1) CR20210336A (cg-RX-API-DMAC7.html)
EC (1) ECSP21044843A (cg-RX-API-DMAC7.html)
IL (2) IL318278A (cg-RX-API-DMAC7.html)
MA (1) MA54551A (cg-RX-API-DMAC7.html)
MX (1) MX2021007426A (cg-RX-API-DMAC7.html)
PE (1) PE20220277A1 (cg-RX-API-DMAC7.html)
PH (1) PH12021551446A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202106582YA (cg-RX-API-DMAC7.html)
TW (2) TW202504901A (cg-RX-API-DMAC7.html)
WO (1) WO2020132197A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7414827B2 (ja) * 2018-12-20 2024-01-16 インサイト・コーポレイション アクチビン受容体様キナーゼ-2の阻害剤としてのイミダゾピリダジン及びイミダゾピリジン化合物
CA3156007A1 (en) 2019-09-27 2021-04-01 Disc Medicine, Inc. METHODS OF TREATING MYELOFIBROSE AND ASSOCIATED CONDITIONS
US12508262B2 (en) 2020-04-30 2025-12-30 Keros Therapeutics, Inc. Methods of using ALK2 inhibitors
AU2021273014A1 (en) 2020-05-13 2022-11-17 AbbVie Deutschland GmbH & Co. KG Anti-hemojuvelin (HJV) antibodies for treating anemia of chronic disease
ES3075793T3 (en) 2020-05-13 2026-08-07 Disc Medicine Inc Anti-hemojuvelin (hjv) antibodies for treating myelofibrosis
US11840546B2 (en) * 2020-06-12 2023-12-12 Incyte Corporation Imidazopyridazine compounds and uses thereof
WO2022098812A1 (en) 2020-11-04 2022-05-12 Keros Therapeutics, Inc. Methods of treating iron overload
CN118119619A (zh) * 2021-10-18 2024-05-31 上海美悦生物科技发展有限公司 Sik抑制剂及其组合物、制备方法和用途
KR102961396B1 (ko) 2022-11-28 2026-05-08 계명대학교 산학협력단 신규한 pim 키나아제 억제제 및 이의 용도

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6355653B1 (en) 1999-09-06 2002-03-12 Hoffmann-La Roche Inc. Amino-triazolopyridine derivatives
PT1283839E (pt) 2000-05-26 2005-08-31 Schering Corp Antagonistas do receptor a2a da adenosina
EP1294358B1 (en) 2000-06-28 2004-08-18 Smithkline Beecham Plc Wet milling process
TW200300686A (en) 2001-11-30 2003-06-16 Schering Corp Adenosine A2a receptor antagonists
EP1615931A1 (en) 2003-04-09 2006-01-18 Biogen Idec MA Inc. Triazolopyrazines and methods of making and using the same
JP2005343889A (ja) 2004-05-06 2005-12-15 Taisho Pharmaceut Co Ltd イミダゾピリジン誘導体
DE602005023763D1 (de) 2004-11-04 2010-11-04 Vertex Pharma Als inhibitoren von proteinkinasen geeignete pyrazoloä1,5-aüpyrimidine
GEP20125658B (en) * 2006-11-22 2012-10-10 Incyte Corp Imidazotriazines and imidazo pyrimidines as kinase inhibitors
HUP0700395A2 (en) 2007-06-07 2009-03-02 Sanofi Aventis Substituted [1,2,4] triazolo [1,5-a] quinolines, process for their preparation, pharmaceutical compositions thereof, and intermediates
EP2740731B1 (en) 2007-06-13 2016-03-23 Incyte Holdings Corporation Crystalline salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
CL2008001709A1 (es) 2007-06-13 2008-11-03 Incyte Corp Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
KR101150581B1 (ko) * 2007-07-26 2012-06-11 노파르티스 아게 유기 화합물
EA201000615A1 (ru) * 2007-10-17 2010-12-30 Новартис Аг Производные имидазо[1,2-а]пиридина, применимые в качестве ингибиторов апк (активиноподобной киназы)
JP2012533545A (ja) 2009-07-14 2012-12-27 ベス・イスラエル・ディーコネス・メディカル・センター,インコーポレイテッド 肝臓の増殖を増大させる方法
EA202091303A3 (ru) 2010-05-21 2021-05-31 Инсайт Холдингс Корпорейшн Композиция ингибитора jak для местного применения
JP5926727B2 (ja) 2010-07-28 2016-05-25 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH 置換イミダゾ[1,2−b]ピリダジン
EP2463289A1 (en) 2010-11-26 2012-06-13 Almirall, S.A. Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors
US20140171434A1 (en) 2011-01-11 2014-06-19 Bayer Pharma Aktiengessellschaft Substituted imidazopyridines and imidazopyridazines and the use thereof
JP6430383B2 (ja) 2012-09-28 2018-11-28 ヴァンダービルト ユニバーシティーVanderbilt University 選択的bmp阻害剤としての縮合複素環化合物
MX2015005375A (es) 2012-11-07 2015-07-21 Hoffmann La Roche Compuestos de triazolo.
JP6542192B2 (ja) 2013-03-14 2019-07-10 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドThe Brigham and Women’s Hospital, Inc. Bmp阻害剤およびその使用方法
US20170107216A1 (en) 2015-10-19 2017-04-20 Incyte Corporation Heterocyclic compounds as immunomodulators
MD3377488T2 (ro) 2015-11-19 2023-02-28 Incyte Corp Compuși heterociclici ca imunomodulatori
ES2916874T3 (es) 2015-12-17 2022-07-06 Incyte Corp Derivados de N-fenil-piridina-2-carboxamida y su uso como moduladores de la interacción proteína/proteína PD-1/PD-L1
CA3009474A1 (en) 2015-12-22 2017-06-29 Incyte Corporation Heterocyclic compounds as immunomodulators
ES2906460T3 (es) 2016-05-06 2022-04-18 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
EP3464279B1 (en) 2016-05-26 2021-11-24 Incyte Corporation Heterocyclic compounds as immunomodulators
SG11201811414TA (en) 2016-06-20 2019-01-30 Incyte Corp Heterocyclic compounds as immunomodulators
MA45669A (fr) 2016-07-14 2019-05-22 Incyte Corp Composés hétérocycliques utilisés comme immunomodulateurs
PL3500571T3 (pl) 2016-08-17 2021-06-28 Children's Hospital Medical Center Związki imidazo[1,2-a]pirydynowe, kompozycje je zawierające, sposoby leczenia chorób z ich wykorzystaniem oraz sposoby ich wytwarzania
US20180057486A1 (en) 2016-08-29 2018-03-01 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2018053126A1 (en) * 2016-09-14 2018-03-22 Vanderbilt University Inhibition of bmp signaling, compounds, compositions and uses thereof
US11371744B2 (en) 2016-09-15 2022-06-28 Awi Licensing Llc Ceiling system with air movement
WO2018119286A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Bicyclic heteroaromatic compounds as immunomodulators
US10308644B2 (en) 2016-12-22 2019-06-04 Incyte Corporation Heterocyclic compounds as immunomodulators
EP4223369A1 (en) 2016-12-22 2023-08-09 Incyte Corporation Immunomodulator compounds and methods of use
WO2018119221A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Pyridine derivatives as immunomodulators
WO2018119236A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Triazolo[1,5-a]pyridine derivatives as immunomodulators
WO2018119263A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds derivatives as pd-l1 internalization inducers
US20200054643A1 (en) 2017-01-18 2020-02-20 Vanderbilt University Fused heterocyclic compounds as selective bmp inhibitors
WO2018165569A1 (en) 2017-03-10 2018-09-13 Rutgers, The State University Of New Jersey Therapeutic compounds and methods
KR20190129851A (ko) 2017-03-16 2019-11-20 지앙수 헨그루이 메디슨 컴퍼니 리미티드 헤테로아릴[4,3-c]피리미딘-5-아민 유도체, 이의 제조 방법 및 이의 의학적 용도
MX2019010302A (es) 2017-03-30 2019-11-21 Hoffmann La Roche Isoquinolinas como inhibidores de hpk1.
MA50440A (fr) 2017-10-24 2020-09-02 Bayer Ag Imidazopyridinamides substituées et leur utilisation
AU2019227607C1 (en) 2018-02-27 2023-07-20 Incyte Corporation Imidazopyrimidines and triazolopyrimidines as A2A / A2B inhibitors
JP7414827B2 (ja) 2018-12-20 2024-01-16 インサイト・コーポレイション アクチビン受容体様キナーゼ-2の阻害剤としてのイミダゾピリダジン及びイミダゾピリジン化合物
US11840546B2 (en) 2020-06-12 2023-12-12 Incyte Corporation Imidazopyridazine compounds and uses thereof

Similar Documents

Publication Publication Date Title
JP2022502490A5 (cg-RX-API-DMAC7.html)
JP2022552324A5 (cg-RX-API-DMAC7.html)
KR100363714B1 (ko) 니트레이트-유발된 내성을 치료하기 위한 약학 조성물
JP2023505258A5 (cg-RX-API-DMAC7.html)
JP2019535664A5 (cg-RX-API-DMAC7.html)
HRP20231614T1 (hr) Spojevi pirolotriazina kao tam inhibitori
JP2010510319A5 (cg-RX-API-DMAC7.html)
SI3083625T1 (en) Pyrimidopyrimidinones, useful as Wee-1 kinase inhibitors
JP2011511034A5 (cg-RX-API-DMAC7.html)
ME01507B (me) Imidazotriazini i imidazopirimidini kao inhibitori kinaze
JP2013523884A5 (cg-RX-API-DMAC7.html)
HRP20200575T1 (hr) Spojevi karbamata i postupci pripremanja i korištenja istih
JP2013523889A5 (cg-RX-API-DMAC7.html)
ME02906B (me) Derivati pirazolopirolidina i njihova upotreba u liječenju bolesti
JP2016525092A5 (cg-RX-API-DMAC7.html)
JP2025514386A5 (cg-RX-API-DMAC7.html)
RU2017121044A (ru) Производные амидотиадиазола в качестве ингибиторов надфн-оксидазы
JP2023525762A5 (cg-RX-API-DMAC7.html)
RU2019123319A (ru) Пиразолопиримидины и способы их применения
IL318278A (en) Imidazopyridazine and imidazopyridine compounds and their use
AU2014229468A1 (en) Combination of an EGFR T790m inhibitor and an EGFR inhibitor for the treatment of non-small cell lung cancer
JP2014511355A5 (cg-RX-API-DMAC7.html)
JP2020536915A5 (cg-RX-API-DMAC7.html)
RU2020114670A (ru) Бициклические соединения для применения в качестве ингибиторов rip1 киназы
RU2015120217A (ru) Замещенные 1,6-нафтиридины